ClinicalTrials.gg
RecruitingNCT06242470Updated Oct 28, 2026

A Study of MGC026 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of MGC026 Dose Escalation and MGC026 Dose for Expansion in Advanced Solid Tumor, Advanced Cancer and Metastatic Cancer, sponsored by MacroGenics. Recruiting at 12 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by MacroGenics · Phase 1, Interventional, and Treatment

How we know · 23 judgments

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Oct 28, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
394
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 344 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
161st of 1,866
394 · median 43
Started
2024
with 76 others
Phase 1
710 of 2,057
127 open now
Primary completion
2028-10
later than 423 of 542 live
Registered
1,836th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 161st largest by planned enrollment of the 1,866 interventional ones that give a count, is one of 77 that started in 2024, is one of 710 in phase 1, reaches primary completion later than 423 of the 542 other live ones, and was the 1,836th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

344 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion in Module A of the study. Combination therapy with pembrolizumab will occur in Module B of the study Participants will receive vobramitamab tavatecan by intravenous (IV) infusion. The dose of vobramitamab tavatecan will be assigned at the time of enrollment. Pembrolizumab will be administered at 200 mg every 3 weeks. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood and tumor samples collected for research purposes.

03

Conditions studied

  • Advanced Solid Tumor
  • Advanced Cancer
  • Metastatic Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Non Small Cell Lung Cancer
  • Small-cell Lung Cancer
  • Bladder Cancer
  • Sarcoma
  • Endometrial Cancer
  • Melanoma
  • Castration Resistant Prostatic Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Gastro-esophageal Cancer
  • Pancreas Cancer
  • Clear Cell Renal Cell Carcinoma
  • Hepatocellular Carcinoma
  • Platinum-resistant Ovarian Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Esophageal Squamous Cell Cancer (SCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years old, able to provide
  • Adequate performance and laboratory parameters
  • Availability of archival or formalin-fixed paraffin-embedded tumor tissue sample. Participants may undergo a fresh tumor to obtain a specimen for testing if an archival tumor sample is not available. Participants with no available archival tissue sample who cannot safely undergo a fresh biopsy as determined by consultation between the sponsor and investigator are eligible
  • Unresectable, locally advanced or solid tumors including: squamous cell cancer (SCC) of the head and neck, esophageal SCC, squamous and non-squamous non-small cell lung cancer, small cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, castration resistant prostate cancer, breast cancer, ovarian cancer, cervical cancer, colorectal cancer gastric or gastroesophageal cancer, pancreatic carcinoma, clear cell renal cell cancer or hepatocellular cancer.
  • per v1.1. Participants with metastatic CRPC without measurable disease are eligible.
  • Must be willing to use highly effective methods of from the time of consent through 7 months after discontinuation of MGC026.
  • Not pregnant or breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
  • Another cancer that required treatment within the past 2 years, with the exception of those with low risk of cancer spreading or death such as adequately treated non melanomatous skin cancer, localized prostate cancer (Gleason Score \< 6), or carcinoma in situ.
  • Patients with history of prior central nervous system (CNS) must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of on magnetic resonance imaging, computed tomography or positron emission tomography, or history of or cord compression at the time of enrollment.
  • Treatment with surgery, systemic cancer therapy, immunotherapy, chimeric antigen receptor-T therapy, or anti-hormonal within protocol specified intervals.
  • Prior treatment with any B7-H3 targeted agent for cancer or any ADC with a topoisomerase payload.
  • Prior autologous or allogeneic stem cell or solid organ transplant.
  • cardiovascular, pulmonary, or gastrointestinal disorders.
  • Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 1 week of first study drug administration.
  • Known history of or C infection or known positive test for hepatitis B surface antigen or core antigen, or polymerase chain reaction.
  • Known positive testing for or history of acquired immune deficiency syndrome.
  • History of primary immunodeficiency.
  • Major trauma or major surgery within 4 weeks of first study drug administration.
  • Known to recombinant proteins.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
394 participants (estimated)

Study arms

  • Experimental
    Module A Cohort 1

    MGC026 is a topoisomerase 1 inhibitor (TOP1i)-based ADC that targets B7-H3 administered IV every 3 weeks.

    Biological: MGC026 Dose Escalation

  • Experimental
    Module A Cohort 2

    Biological: MGC026 Dose Escalation

  • Experimental
    Module A Cohort 3

    Biological: MGC026 Dose Escalation

  • Experimental
    Module A Cohort 4

    Biological: MGC026 Dose Escalation

  • Experimental
    Module A Cohort 5

    Biological: MGC026 Dose Escalation

  • Experimental
    Module A Cohort 6

    Biological: MGC026 Dose Escalation

  • Experimental
    Module A Expansion cohort 1

    Biological: MGC026 Dose for Expansion

  • Experimental
    Module A Expansion cohort 2

    Biological: MGC026 Dose for Expansion

  • Experimental
    Module A Expansion cohort 3

    Biological: MGC026 Dose for Expansion

  • Experimental
    Module A Expansion cohort 4

    Biological: MGC026 Dose for Expansion

  • Experimental
    Module A Expansion Cohort 5

    Biological: MGC026 Dose for Expansion

  • Experimental
    Module A Expansion Cohort 6

    Biological: MGC026 Dose for Expansion

  • Experimental
    Module A Expansion Cohort 7

    Biological: MGC026 Dose for Expansion

  • Experimental
    Module A Expansion Cohort 8

    Biological: MGC026 Dose for Expansion

  • Experimental
    Module B Part 1, Dose Level 1

    Biological: Pembrollizumab · Biological: vobramitamab tavatecan

  • Experimental
    Module B Part 1, Dose Level 2

    Module B Part 2, Dose Expansion

    Biological: MGC026 Dose for Expansion · Biological: Pembrollizumab

Interventions

  • BiologicalMGC026 Dose Escalation

    Escalating doses of MGC026

  • BiologicalMGC026 Dose for Expansion

    MGC026 recommended dose for expansion

  • BiologicalPembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    200 mg, IV, every 3 weeks.

    Also known as: Keytruda

  • Biologicalvobramitamab tavatecan

    less than RDE dose level, IV, every 3 weeks

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest.

    Time frame: Throughout the study, up to 135 weeks

Secondary outcomes

  1. Overall response rate in advanced solid tumors

    The objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) is used to estimate the proportion of participants in the Response Evaluable population who achieve best overall response of complete response (CR) or partial response (PR) (called responders). Complete response (CR) is defined as disappearance of all target and non-target lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions, and no new lesions

    Time frame: Throughout the study, up to 135 weeks

  2. Duration of response (DoR) in advanced solid tumors

    DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented progression or death from any cause, whichever occurs first. (RECIST 1.1) is used to classify responses.

    Time frame: Throughout the study, up to 135 weeks

  3. ORR rate in metastatic castration resistant prostate cancer (mCRPC)

    The ORR per Prostate Cancer Working Group 3 (PCWG3) criteria is estimated as the proportion of participants in the Response Evaluable population who achieve best overall response of CR or PR (called responders).

    Time frame: Throughout the study, up to 135 weeks

  4. DoR in mCRPC

    DoR is defined as the time from the date of initial response (CR or PR) to the date of first documented progression, per PCWG3 criteria or death from any cause, whichever occurs first.

    Time frame: Throughout the study, up to 135 weeks

  5. Mean (standard deviation [SD]) of vobramitamab tavatecan total and conjugated antibody maximum serum concentration (Cmax)

    The maximum concentration in the bloodstream at the end of the infusion.

    Time frame: Cycle 1 Day 1: at baseline, end of infusion (EOI) approximately 1 hr, 4hrs after EOI, Day 2 and Day 4.

  6. Mean (standard deviation [SD]) of vobramitamab tavatecan unconjugated payload Cmax

    The maximum concentration in the bloodstream at the end of the infusion.

    Time frame: Cycle 1 Day 1: at baseline, end of infusion (EOI) approximately 1 hr, 4hrs after EOI, Day 2 and Day 4.

  7. Mean (SD) of vobramitamab tavatecan total and conjugated antibody area under the time concentration curve (AUC)

    Calculated exposure to MGC026

    Time frame: Cycle 1 Day 1: at baseline, EOI approximately 1 hr, 4hrs after EOI, Day 2, Day 4, Day 8, Day 15, and predose Cycle 2 Day 1

  8. Mean (SD) of vobramitamab tavatecan unconjugated payload AUC

    Calculated exposure to MGC026

    Time frame: Cycle 1 Day 1: at baseline, EOI approximately 1 hr, 4hrs after EOI, Day 2, Day 4, Day 8, Day 15, and predose Cycle 2 Day 1

  9. Number of participants who develop anti-vobramitamab tavatecan antibodies (immunogenicity)

    Development of anti-MGC026 antibodies in the bloodstream

    Time frame: Day 1, Day 15, and Day 1 of every 21-day cycle, throughout the study, average of 1 year.

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Oct 2028, 55 months after the start.

Of 289 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 55 months is above that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion May 2028 → Oct 2028 and completion Oct 2028 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2024
First posted
Feb 5, 2024
StartActual
Mar 6, 2024
Primary completionEst.
Oct 2028was May 2028
CompletionEst.
Apr 2029was Oct 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
May 2028→Oct 2028
Oct 28, 2026
Study completion
Oct 2028→Apr 2029
Oct 28, 2026
Enrollment
250→394
Oct 28, 2026
Interventions
Added Biological: Pembrollizumab·Biological: vobramitamab tavatecan. Arm changed Cohort 1→Module A Cohort 1; Cohort 2→Module A Cohort 2; Cohort 3→Module A Cohort 3; Cohort 4→Module A Cohort 4; Cohort 5→Module A Cohort 5; Cohort 6→Module A Cohort 6; Expansion cohort 1→Module A Expansion cohort 1; Expansion cohort 2→Module A Expansion cohort 2; Expansion cohort 3→Module A Expansion cohort 3; Expansion cohort 4→Module A Expansion cohort 4; Expansion Cohort 5→Module A Expansion Cohort 5; Expansion Cohort 6→Module A Expansion Cohort 6. Arms added: Module A Expansion Cohort 7·Module A Expansion Cohort 8·Module B Part 1, Dose Level 1·Module B Part 1, Dose Level 2
Oct 28, 2026
Secondary outcomes
5 edited
What changed in the outcomes
  • EditedMean (standard deviation [SD]) of MGC026vobramitamab tavatecan total and conjugated antibody maximum serum concentration (Cmax)Time frame: Cycle 1 Day 1: at baseline, end of infusion (EOI) approximately 1 hr, 4hrs after EOI, Day 2 and Day 4.
  • EditedMean (standard deviation [SD]) of MGC026vobramitamab tavatecan unconjugated payload CmaxTime frame: Cycle 1 Day 1: at baseline, end of infusion (EOI) approximately 1 hr, 4hrs after EOI, Day 2 and Day 4.
  • EditedMean (SD) of MGC026vobramitamab tavatecan total and conjugated antibody area under the time concentration curve (AUC)Time frame: Cycle 1 Day 1: at baseline, EOI approximately 1 hr, 4hrs after EOI, Day 2, Day 4, Day 8, Day 15, and predose Cycle 2 Day 1
  • EditedMean (SD) of MGC026vobramitamab tavatecan unconjugated payload AUCTime frame: Cycle 1 Day 1: at baseline, EOI approximately 1 hr, 4hrs after EOI, Day 2, Day 4, Day 8, Day 15, and predose Cycle 2 Day 1
  • EditedNumber of participants who develop anti-MGC026vobramitamab tavatecan antibodies (immunogenicity)Time frame: Day 1, Day 15, and Day 1 of every 21-day cycle, throughout the study, average of 1 year.
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Primary completion May 2028→Oct 2028
    Study completion Oct 2028→Apr 2029
    Enrollment 250→394
    Secondary outcomes 5 edited
    What changed in the outcomes
    • EditedMean (standard deviation [SD]) of MGC026vobramitamab tavatecan total and conjugated antibody maximum serum concentration (Cmax)Time frame: Cycle 1 Day 1: at baseline, end of infusion (EOI) approximately 1 hr, 4hrs after EOI, Day 2 and Day 4.
    • EditedMean (standard deviation [SD]) of MGC026vobramitamab tavatecan unconjugated payload CmaxTime frame: Cycle 1 Day 1: at baseline, end of infusion (EOI) approximately 1 hr, 4hrs after EOI, Day 2 and Day 4.
    • EditedMean (SD) of MGC026vobramitamab tavatecan total and conjugated antibody area under the time concentration curve (AUC)Time frame: Cycle 1 Day 1: at baseline, EOI approximately 1 hr, 4hrs after EOI, Day 2, Day 4, Day 8, Day 15, and predose Cycle 2 Day 1
    • EditedMean (SD) of MGC026vobramitamab tavatecan unconjugated payload AUCTime frame: Cycle 1 Day 1: at baseline, EOI approximately 1 hr, 4hrs after EOI, Day 2, Day 4, Day 8, Day 15, and predose Cycle 2 Day 1
    • EditedNumber of participants who develop anti-MGC026vobramitamab tavatecan antibodies (immunogenicity)Time frame: Day 1, Day 15, and Day 1 of every 21-day cycle, throughout the study, average of 1 year.
    Interventions Added Biological: Pembrollizumab·Biological: vobramitamab tavatecan. Arm changed Cohort 1→Module A Cohort 1; Cohort 2→Module A Cohort 2; Cohort 3→Module A Cohort 3; Cohort 4→Module A Cohort 4; Cohort 5→Module A Cohort 5; Cohort 6→Module A Cohort 6; Expansion cohort 1→Module A Expansion cohort 1; Expansion cohort 2→Module A Expansion cohort 2; Expansion cohort 3→Module A Expansion cohort 3; Expansion cohort 4→Module A Expansion cohort 4; Expansion Cohort 5→Module A Expansion Cohort 5; Expansion Cohort 6→Module A Expansion Cohort 6. Arms added: Module A Expansion Cohort 7·Module A Expansion Cohort 8·Module B Part 1, Dose Level 1·Module B Part 1, Dose Level 2
    + 4 other changes: index terms, verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06242470
Lead sponsor
MacroGenics
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Mar 6, 2024
Primary completion
Oct 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Global Trial Manager
Contact
info@macrogenics.com
301-251-5172
Yiyun Dai, MD, PhD
study director · MacroGenics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion